Veracyte reports Q2 EPS 44c, consensus 30c

Reports Q2 revenue $130.164M, consensus $120.9M. “Testing growth continues to exceed our expectations, driven by Decipher which achieved its thirteenth consecutive quarter of over 25% year-over-year volume growth,” said Marc Stapley, Veracyte’s (VCYT) chief executive officer. “This strong result, combined with Afirma volume meeting our expectations and the resolution of the French subsidiary proceedings, has positioned us for incremental investment in our strategic portfolio in the second half of 2025 and beyond, strengthening our confidence in delivering sustained long-term revenue growth. Backed by our differentiated platform and a growing body of clinical evidence, we are deeply committed to improving outcomes for patients around the world.”